Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Because of Vertiv’s concentrated exposure to the data center market, any downturn in spending would greatly impact the firm’s sales and therefore cash generation. In this event, Vertiv has the option ...

Sidley Austin, Simpson Thacher, Norton Rose, White & Case, among others, all announced new corporate partners this week in ...

With private asset ETFs still awaiting regulatory approval, opportunistic issuers are continuing to crank out products that ...

Skilled nursing deals are plentiful, and private equity has a large role to play in their abundance, according to leaders at ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

The number of mergers and acquisitions (M&A) rose this week even as private equity and venture capital funding momentum ...

Baby Boomers are "the luckiest generation" in America and the most entitled in recent history, how did they get so lucky?

Health Affairs' Jeff Byers welcomes Senior Editor Kathleen Haddad back to the program to discuss two recent reports exploring the impacts of private equity on the US health care system.

With private-sector diversity, equity and inclusion policies in the government’s crosshairs, businesses are ditching ...

Foroughi and his two AppLovin co-founders had built the company in five years with just $4 million raised from angel investors, according to the press release that announced the deal. A nice payday ...

Wall Street is still awaiting regulatory approval for the first full-blown private-asset ETFs, but for now opportunistic ...